Filing Flows › AbCellera Biologics (ABCL) › Q1 2026
AbCellera Biologics (ABCL) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 11, 2026
AbCellera Biologics (ABCL) reported revenue of $8.3M for the first quarter 2026 (Q1 2026), +96% from a year earlier and -81% from the quarter before. Operating margin was -691.7%, net loss $43.2M (519.1% of revenue).
AbCellera Biologics, Q1 2026: revenue $8.3M (+96% year over year), operating margin -691.7%, net loss $43.2M, operating cash flow −$33.5M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $8.3M | -81% | +96% |
| Operating profit | −$57.5M | — | — |
| Net earnings | −$43.2M | — | — |
| Operating cash flow | −$33.5M | — | — |
What changed
Revenue was $8.3M in Q1 2026, up 96% year over year and down 81% from the previous quarter. Research fees was the largest line at 98% of revenue. Research fees added $4.1M year over year (up 100%), 99% of the total change.
Operating costs exceeded revenue by $57.5M, an operating margin of -691.7%. Total costs fell 2% while revenue rose 96%. The fastest-growing cost line was Other operating costs (+28%). The quarter ended with a net loss of $43.2M, wider than the previous quarter's $8.9M loss.
Operating cash flow was −$33.5M. Non-cash charges added back $6.8M of depreciation and amortization and $12.0M of share-based compensation. Working capital and other items used $9.2M. Capital expenditures of $3.8M exceeded it, leaving free cash flow of −$37.4M.
Questions
What was AbCellera Biologics' revenue in the first quarter 2026?
AbCellera Biologics (ABCL) reported revenue of $8.3M for the first quarter 2026 (Q1 2026), +96% from a year earlier and -81% from the quarter before.
Was AbCellera Biologics profitable in the first quarter 2026?
Operating loss was $57.5M (-691.7% of revenue) and net loss $43.2M.